In the realm of neurological disorders, epilepsy has long posed significant challenges due to its complex nature and the difficulty in managing its symptoms. Vigabatrin marks a significant advancement in the treatment of epilepsy, being the first “designer” drug specifically tailored to address the needs of patients resistant to conventional medications. Its development and mechanism […]
InvaGen Pharmaceuticals Inc., a wholly-owned subsidiary of Cipla Limited, has announced a voluntary recall of one lot of Vigabatrin for Oral Solution, USP 500mg, to the consumer level in the USA. This recall comes after the discovery of seal integrity issues in the product packaging, which could lead to powder leakage from the pouches. The […]
In an important safety announcement, Cipla Limited revealed that its wholly-owned subsidiary, InvaGen Pharmaceuticals Inc., based in the USA, is conducting a voluntary recall of a specific lot of Vigabatrin for Oral Solution, USP 500mg. This decision to recall was made due to the discovery of seal integrity issues, which have led to the leakage […]
Zydus Lifesciences has bagged final approval for seizures drug Vigabatrin for Oral Solution USP, 500 mg from the US Food and Drug Administration (FDA). Vigabatrin for Oral Solution is a generic version of Sabril for Oral Solution. It is approved to treat refractory complex partial seizures as adjunctive therapy in patients aged two years and […]
Lupin Limited said that it has secured approval for Vigabatrin for Oral Solution USP, 500 mg, an anti-epileptic drug, from the US Food and Drug Administration (FDA). The US pharma regulator approved the abbreviated new drug application (ANDA) of the Lupin product, which is a generic of Sabril for Oral Solution, 500 mg owned by […]